Evidence map›Paper›PMID 35875195›Full record

ReviewMaterials today. Bio2022

Recent progress and perspectives of continuous in vivo testing device.

Tao Ming, Jinping Luo, Yu Xing, Yan Cheng, Juntao Liu, Shuai Sun, Fanli Kong, Shihong Xu, Yuchuan Dai, Jingyu Xie and 2 more

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tao MingAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Jinping LuoAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Yu XingAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Yan ChengObstetrics and Gynecology Department, Peking University First Hospital, Beijing, 100034, PR China.
Juntao LiuAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Shuai SunAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Fanli KongAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Shihong XuAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Yuchuan DaiAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Jingyu XieAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.
Hongyan JinObstetrics and Gynecology Department, Peking University First Hospital, Beijing, 100034, PR China.
Xinxia CaiAerospace Information Research Institute, Chinese Academy of Sciences, Beijing, 100094, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Devices for continuous in-vivo testing (CIVT) can detect target substances in real time, thus providing a valuable window into a patient's condition, their response to therapeutics, metabolic activities, and neurotransmitter transmission in the brain. Therefore, CIVT devices have received increased attention because they are expected to greatly assist disease diagnosis and treatment and research on human pathogenesis. However, CIVT has been achieved for only a few markers, and it remains challenging to detect many key markers. Therefore, it is important to summarize the key technologies and methodologies of CIVT, and to examine the direction of future development of CIVT. We review recent progress in the development of CIVT devices, with consideration of the structure of these devices, principles governing continuous detection, and nanomaterials used for electrode modification. This detailed and comprehensive review of CIVT devices serves three purposes: (1) to summarize the advantages and disadvantages of existing devices, (2) to provide a reference for development of CIVT equipment to detect additional important markers, and (3) to discuss future prospects with emphasis on problems that must be overcome for further development of CIVT equipment. This review aims to promote progress in research on CIVT devices and contribute to future innovation in personalized medical treatments.

Indexed as

AptamerContinuous detection equipmentIn-vivo testingMicrofluidic chipNanomaterial

Identifiers

PMID35875195
PMCPMC9305619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.